Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 187004 dose-ranging study in type 2 diabetes mellitus
2013-003646-16Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI 187004 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Drug-related adverse events. Started Apr 2014; status: completed.
02
Drugs
BI 187004
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003646-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003646-16.